BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31

Biohaven Ltd.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$11.35+0.57 (+5.29%)

Close on Oct 19, 2026

Market cap: $1.71B
P/E (TTM): –
Dividend yield: –

Biohaven Ltd. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30
Depreciation & Amortization	2.26	2.37	2.57	3.13	1.98	2.25	2.46	1.99	1.95	1.45	1.89	1.54	1.83	1.65	0.34	0.38	0.42	0.25	0.69	–
Stock-Based Compensation	19	28	17	22	21	53	13	12	12	35	16	4.46	4.70	3.77	116	17	21	40	13	15
Other Non-Cash Items	0.52	0.84	-5.58	1.16	1.40	2.84	4.95	3.62	2.07	1.06	0.99	1.01	1.94	1.75	-0.73	0	-0.25	0.25	1.46	–
Change in Accounts Payable	1.69	-1.22	-5.85	-2.14	1.51	0.09	-1.72	2.49	-19	19	6.06	-2.52	-2.42	3.75	5.97	-1.65	-0.33	1.93	-2.48	–
Operating Cash Flow	-85	-150	-131	-146	-168	-165	-171	-141	-168	-103	-115	-95	-44	-78	-75	-96	-68	-59	-33	–
Capital Expenditures	-0.45	0	-0.01	-0.01	-0.23	-0.46	-0.05	-0.61	-2.95	-0.44	-0.47	-1.25	-0.60	-0.74	-0.30	-4.52	-1.00	-0.25	-0.20	–
Purchase of Investments	-30	-20	-89	0	-133	-45	-280	-223	-196	-47	-111	-29	-24	-30	-260	0	0	0	–	–
Sale & Maturity of Investments	75	35	75	165	120	210	192	130	101	81	108	89	100	29	–	–	–	–	–	–
Other Investing Activities	–	–	0	-0.02	–	–	-0.39	0	–	–	–	–	–	–	–	–	–	–	–	–
Investing Cash Flow	45	15	-14	165	-16	165	-88	-93	-98	34	-3.91	59	76	-1.06	-264	-4.52	-36	-0.25	-0.20	–
Stock Issued	0	179	189	0	0	0	271	76	–	–	243	0	–	–	–	–	–	–	–	–
Other Financing Activities	0	0	-0.19	0	0	0	0	0	1.04	1.22	-1.86	1.86	0	0	0	0	0	0	0	–
Financing Cash Flow	3.80	179	189	0.12	250	0.37	273	80	321	3.42	245	-40	-20	27	530	128	87	23	-252	–
Foreign Exchange Rate Adjustments	0.00	0.02	0	0.01	-0.04	0.02	0.09	0	-0.01	-0.01	-0.31	-0.04	-0.16	0.02	0.43	0	0	0	–	–
Net Change in Cash	-36	44	44	19	66	0.15	15	-154	55	-65	126	-76	11	-52	191	27	-17	-36	-286	–
Free Cash Flow	-86	-150	-131	-146	-168	-166	-171	-142	-171	-103	-115	-96	-45	-78	-76	-100	-69	-59	-33	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -310.8%

Financial strength

Current ratio: 4.73
Debt to equity: 21.23
Debt to assets: 70.0%
Cash to current liabilities: 379.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 139.89
Dividend yield: –